|
gptkbp:instanceOf
|
gptkb:protein
gptkb:drug
immunotherapy
|
|
gptkbp:administeredBy
|
intravenous injection
|
|
gptkbp:affiliatedWith
|
cytokines
|
|
gptkbp:approvalYear
|
1992
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:L03AC01
|
|
gptkbp:biosimilar
|
Yes
|
|
gptkbp:brand
|
gptkb:Proleukin
|
|
gptkbp:CASNumber
|
gptkb:110942-02-4
|
|
gptkbp:contraindication
|
organ transplant
severe cardiac disease
|
|
gptkbp:discoveredBy
|
gptkb:Cetus_Corporation
|
|
gptkbp:genericName
|
gptkb:aldesleukin
|
|
gptkbp:halfLife
|
~85 minutes
|
|
gptkbp:hasMolecularFormula
|
C690H1116N194O203S6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Aldesleukin
|
|
gptkbp:indication
|
immunotherapy
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
Clinigen
|
|
gptkbp:mechanismOfAction
|
interleukin-2 receptor agonist
|
|
gptkbp:origin
|
gptkb:Bacteria
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:producedBy
|
recombinant DNA technology
|
|
gptkbp:promotion
|
gptkb:natural_killer_cells
T lymphocytes
|
|
gptkbp:proteinSequence
|
recombinant human interleukin-2
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
gptkb:capillary_leak_syndrome
fever
nausea
vomiting
chills
hypotension
|
|
gptkbp:target
|
gptkb:IL-2_receptor
|
|
gptkbp:UNII
|
QDL8Q5289D
|
|
gptkbp:usedFor
|
metastatic melanoma
metastatic renal cell carcinoma
|
|
gptkbp:bfsParent
|
gptkb:Il-2
|
|
gptkbp:bfsLayer
|
6
|